Xu Weilin, Chen Xiu, Deng Fei, Zhang Jian, Zhang Wei, Tang Jinhai
Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, People's Republic of China.
Onco Targets Ther. 2020 Jun 22;13:5887-5899. doi: 10.2147/OTT.S253056. eCollection 2020.
Neoadjuvant chemotherapy (NAC) largely increases operative chances and improves prognosis of the local advanced breast cancer patients. However, no specific means have been invented to predict the therapy responses of patients receiving NAC. Therefore, we focus on the alterations of tumor tissue-related microenvironments such as stromal tumor-infiltrating lymphocytes status, cyclin-dependent kinase expression, non-coding RNA transcription or other small molecular changes, in order to detect potentially predicted biomarkers which reflect the therapeutic efficacy of NAC in different subtypes of breast cancer. Further, possible mechanisms are also discussed to discover feasible treatment targets. Thus, these findings will be helpful to promote the prognosis of breast cancer patients who received NAC and summarized in this review.
新辅助化疗（NAC）在很大程度上增加了局部晚期乳腺癌患者的手术机会并改善了其预后。然而，尚未发明出预测接受NAC治疗患者治疗反应的具体方法。因此，我们关注肿瘤组织相关微环境的变化，如基质肿瘤浸润淋巴细胞状态、细胞周期蛋白依赖性激酶表达、非编码RNA转录或其他小分子变化，以检测可能反映NAC在不同亚型乳腺癌中治疗效果的潜在预测生物标志物。此外，还讨论了可能的机制以发现可行的治疗靶点。因此，这些发现将有助于改善接受NAC治疗的乳腺癌患者的预后，并在本综述中进行总结。
